Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Jan 17:8:16.
doi: 10.1186/s13756-019-0466-x. eCollection 2019.

Emergence of vancomycin-resistant enterococci in Switzerland: a nation-wide survey

Niccolò Buetti  1   2   3 , Nasstasja Wassilew  1 , Viktorija Rion  2 , Laurence Senn  4 , Céline Gardiol  5 , Andreas Widmer  6 , Jonas Marschall  1 ; for Swissnoso
Collaborators, Affiliations

Emergence of vancomycin-resistant enterococci in Switzerland: a nation-wide survey

Niccolò Buetti et al. Antimicrob Resist Infect Control. .

Abstract

This nation-wide survey on the epidemiology of vancomycin-resistant enterococci (VRE) included 142 healthcare institutions and showed an increasing number of VRE colonizations and infections in Switzerland, probably for the most part due to nosocomial dissemination. The introduction and spread of a new clone, gaps in VRE screening policies as well as heterogeneity regarding the management of VRE clusters may be possible explanations.

Keywords: Hospital-acquired; Nosocomial; Outbreak; ST796; VRE; Vancomycin-resistant enterococci.

PubMed Disclaimer

Conflict of interest statement

Not applicableNot applicable (no individual person’s data).The authors declare that they have no competing interests.Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Figures

Fig. 1
Fig. 1
Survey institutions and respondents. Note: *Most of the 61 institutions that did not complete the survey were small hospitals (i.e., only three non-respondent hospitals had > 200 beds)
Fig. 2
Fig. 2
Number of VRE cases detected (a) and VRE incidence per day (b) from 2015 to 2018 in 142 Swiss institutions. Note: Fig. B with trend line (dotted). VRE: vancomycin resistant enterococci. *in 2018 only data for the first quarter were included
Fig. 3
Fig. 3
VRE outbreaks in Switzerland per year from 1st January 2015 to early April 2018. Note:* in 2018 only data until the beginning of April were included
See this image and copyright information in PMC

References

    1. Rubinstein E, Keynan Y. Vancomycin-resistant enterococci. Crit Care Clin. 2013;29(4):841–852. doi: 10.1016/j.ccc.2013.06.006. - DOI - PubMed
    1. Prematunge C, MacDougall C, Johnstone J, Adomako K, Lam F, Robertson J, et al. VRE and VSE bacteremia outcomes in the era of effective VRE therapy: a systematic review and meta-analysis. Infect Control Hosp Epidemiol. 2016;37(1):26–35. doi: 10.1017/ice.2015.228. - DOI - PMC - PubMed
    1. Tacconelli E, Carrara E, Savoldi A, Harbarth S, Mendelson M, Monnet DL, et al. Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis. Lancet Infect Dis. 2018;18(3):318–327. doi: 10.1016/S1473-3099(17)30753-3. - DOI - PubMed
    1. ECDC. Surveillance of antimicrobial resistance in Europe. 2016. Available from: https://ecdc.europa.eu/sites/portal/files/documents/AMR-surveillance-Eur.... 2017.
    1. Thierfelder C, Keller PM, Kocher C, Gaudenz R, Hombach M, Bloemberg GV, et al. Vancomycin-resistant Enterococcus. Swiss Med Wkly. 2012;w13540:142. - PubMed

Publication types

MeSH terms